Tocris/Noladin ether/1411/25/25 mg

Biological Activity

Endogenous agonist for the GPR55 and CB₁ receptors (EC₅₀ values are 10 and 37 nM respectively) that displays selectivity over CB₂ receptors (K_i values are 21.2 nM and > 3mM at CB₁ and CB₂ respectively). Causes sedation, hypothermia, intestinal immobility and mild antinociception in vivo. Attenuates sensory neurotransmission in rat mesenteric arteries via GPR55.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Preparing Stock Solutions

The following data is based on the product molecular weight 364.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Product Datasheets

References

References are publications that support the products' biological activity.

Duncan et al (2004) Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB₁/CB₂ G_i/o linked receptor. Br.J.Pharmacol. 142 509 PMID: 15148262

Hanus et al (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB₁ receptor. Proc.Natl.Acad.Sci.U.S.A. 98 3662 PMID: 11259648

Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092 PMID: 17876302

Sugiura et al (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. J.Biol.Chem. 274 2794 PMID: 9915812

Suhara et al (2000) Synthesis and biological activities of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues. Chem.Pharm.Bull. 48 903 PMID: 10923815